The iconic German tuner continues to commemorate some of Audi Sport's best-known models; now it's time for the RS 7 to shine under the spotlight on the aftermarket realm's red carpet. Late last year, ...

Discover why Abbott Laboratories (ABT) earns a buy rating with strong fundamentals, dividend growth, and growth prospects.

ABT Sportsline has been turning various Volkswagen Group vehicles into better and sometimes faster rides for many years, and you can probably remember the Legacy Edition (LE) versions of the RS 6 ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor ...

The 2020 Audi S8 is a powerhouse to begin with. From the factory, Audi has fitted a 4.0-liter twin-turbo V8 that produces 571 horsepower and 590 pound feet of torque. That’s more than enough for most ...

Abbott Laboratories (NYSE:ABT) is scheduled to announce its second-quarter earnings on Thursday, July 17, 2025. For traders who focus on events, examining the historical reactions of the stock to ...

Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1.34 ...

The €110,000 (US$120,000) Audi RS6 Avant has been the highest performance variant in the Audi A6 range since 2002, and is now only available in estate car guise: an eccentric combination of 600 hp ...

Even the best of the best can still enjoy an upgrade sometimes. Compared with the standard model, the RS Q8 Signature Edition can really fly. It ups the horsepower from 600 hp to 800 hp, increases ...

ABT-263 and its structural analogues ABT-199 and ABT-737 inhibit B-cell lymphoma 2 (Bcl-2), BCL2L1 long isoform (Bcl-xL) and BCL2L2 (Bcl-w) proteins and promote cancer cell death. Here, we show that ...

The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virologic response in a phase 2 study ...